the strategic moment big pharma spends heavily on r&d big pharma projects global sales out:...

14
The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net income ~ 20 - 30% on sales 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 1990 1995 1998 1999 2000 2001 U.S. overseas total

Upload: hilary-malone

Post on 27-Dec-2015

218 views

Category:

Documents


3 download

TRANSCRIPT

Page 1: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

The Strategic Moment

Big Pharma spends heavily on R&D

Big Pharma projects global sales out:

>>> 2010 $600 billion >>> 2020 $1,200 billion

Big Pharma net income ~ 20 - 30% on sales

0

5,000

10,000

15,000

20,000

25,000

30,000

35,000

1990 1995 1998 1999 2000 2001

U.S.

overseas

total

Page 2: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

The Strategic Moment

Big Pharma R&D spending rises, results elusive

Page 3: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

The Strategic Moment

Big Pharma looks to increased outsourcing of R&D

to speed drug discovery

to convert fixed costs into variable costs

to tap the large pool of world class talent in science and technology in China, India, Russia

Page 4: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

1993 1.6

1995 2.4

1997 3.6

1999 5.5

2001 7.0

2003 9.3

Growth of the Contract Research Market for outsourcing drug

discovery R&D

0.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

8.0

9.0

10.0

1993 1995 1997 1999 2001 2003

(billion US$)

(billion US$)

Page 5: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

The Strategic Impasse

Big Pharma looks to increased outsourcing of R&D

Big Pharma sees the large pool of world class talent in science and technology in China, India, Russia

Big Pharma sees the tremendous cost-advantages potentially realizable by doing more in China, India, Russia

Big Pharma have no visibility into CROs in China, India, Russia

Outsourcing projects are a notorious headache to manage

Cannot see into the Black Box

Cannot solve the mutual trust and communication issue

Cannot solve the day-to-day fine-grained project tracking issues

Page 6: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

Breaking through the Strategic Impasse: ChinaBig Pharma sees world class talent in science and technology in China with tremendous cost advantages there

The solution:

CalenTrack as the fine-grained off-site research management tool

The Unique Node to let Big Pharma see inside the Black Box

The Unique Node matches projects needs of Big Pharma with top-talent CROs within China

CalenTrack guarantees transparency, total tracking

China is a Black Box to Big Pharma

Who can we deal with? Who can we trust?

Page 7: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

Breaking through the Strategic Impasse: China

Big Pharma sees world class talent in science and technology in China with tremendous cost advantages there

The solution:

CalenTrack as the fine-grained off-site research management tool

The Unique Node to let Big Pharma see inside the Black Box

The Unique Node matches projects needs of Big Pharma with top-talent CROs within China

CalenTrack guarantees transparency, total tracking

CalenTrack is a tool to protect IP rights

Page 8: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

Big Pharma

Need to outsource more research

Need to find reliable capable CROs

CHINA

A BLACK BOX

Fear factors:

Business culture

Knowing who is who

Whom do I trust?

How do I get things done?

Page 9: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

Big Pharma

research needs

The Unique Node with CalenTrack

trusted CROtrusted CRO

trusted CRO

trusted CROCHINA

with good connections:

a deep well of talent

Page 10: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

CalenTrack lets you see inside the Black Box

CalenTrack solves the fine-grained project tracking issues

CalenTrack enables managers to respond quickly to follow promising leads and to correct mistakes in good time.

Using CalenTrack enables closer tracking and targetting of effort, with the result that you get more done with fewer researchers.

Page 11: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

CalenTrack makes the CRO team transparent

CalenTrack enables communication with a decentralized team that is precisely focused on specific data and research findings.

CalenTrack puts all data files created by the team where they can be seen and shared.

Using CalenTrack the off-site manager can track at a glance individual contributors, their time spent by task, and their progress against milestones.

With CalenTrack the manager can keep a close eye on the big picture at the project level, encompassing the project team, the project data, and project supplies.

Page 12: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

CalenTrack is a tool for improving CRO performance CalenTrack is a tool for building mutual trust

Using CalenTrack enables closer tracking of CRO performance. Companies employing contract research organizations around the world will be able to oversee their operations in detail, and compare and rate their performance with precision.

High-performing contract research organizations using CalenTrack can establish a track record documenting their superior performance, and establish their credentials as preferred service providers.

Both sides gain – mutual trust unblocks the deal flow

Page 13: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

CalenTrack IP Vault™ holds a secure fine-grained record to verify to all IP claims

CalenTrack is a tool for safeguarding IP rights

CalenTrack builds a detailed record of all work done by the research team. CalenTrack builds a comprehensive record of what work was done when, and by whom, including all data files, and communications threads among the team members.

Page 14: The Strategic Moment Big Pharma spends heavily on R&D Big Pharma projects global sales out: >>> 2010 $600 billion >>> 2020 $1,200 billion Big Pharma net

CalenTrack is a full featured tool for research management

Manage performance

Manage communications

Manage time constraints

Manage inventory

Manage costs

Track project task history

Track working hours

Track IP issues

Control deadlines

Monitor productivity

Monitor budgets

Identify problems and risks

Generate daily, weekly and monthly reports

Document results, e-archiving

Built-in search engine

Quick access to user-selected databases